Canada markets close in 6 hours 8 minutes

  • S&P/TSX

    18,330.41
    -91.19 (-0.50%)
     

  • S&P 500

    3,863.14
    -7.15 (-0.18%)
     

  • DOW

    31,477.31
    +85.79 (+0.27%)
     

  • CAD/USD

    0.7908
    -0.0004 (-0.05%)
     

  • CRUDE OIL

    60.87
    +1.12 (+1.87%)
     

  • BTC-CAD

    64,174.04
    +2,032.91 (+3.27%)
     

  • CMC Crypto 200

    1,013.95
    +25.85 (+2.62%)
     

  • GOLD FUTURES

    1,709.00
    -24.60 (-1.42%)
     

  • RUSSELL 2000

    2,240.91
    +9.40 (+0.42%)
     

  • 10-Yr Bond

    1.4740
    +0.0590 (+4.17%)
     

  • NASDAQ

    13,292.67
    -66.12 (-0.49%)
     

  • VOLATILITY

    24.27
    +0.17 (+0.71%)
     

  • FTSE

    6,640.15
    +26.40 (+0.40%)
     

  • NIKKEI 225

    29,559.10
    +150.93 (+0.51%)
     

  • CAD/EUR

    0.6554
    +0.0009 (+0.14%)
     
MARKETS LIVE BLOG:

STOCKS TRADE MIXED AS BOND YIELDS SURGE

Private payrolls rose less than expected in February: ADP

Accused Capitol Rioter Apologizes For Threat To Assassinate Rep. Ocasio-Cortez

David Moye
·Reporter, HuffPost
·2 min read

A Texas man facing federal charges linked to the Jan. 6 insurrection at the U.S. Capitol is apologizing for taking part in the storming of the Capitol and for threatening Democratic Rep. Alexandria Ocasio-Cortez and a Capitol Police officer.

Garret Miller released a statement on Monday through his attorney claiming that he stormed the Capitol after becoming convinced by Donald Trump’s election fraud lies. The 34-year-old Miller had previously tweeted “Assassinate AOC” and threatened a Capitol Police officer who fatally shot a fellow rioter.

“I am ashamed of my comments,” Miller’s statement read. “I was in Washington, D.C. on January 6, 2021, because I believed I was following the instructions of former President Trump and he was my president and the commander-in-chief. His statements also had me believing the election was stolen from him.”

“Nevertheless, I fully recognize Joe Biden is now the President of the United States and that the election is over. Donald Trump is no longer president and I would not have any reason to continue to follow his lead.”

As for his threats against the officer and the New York lawmaker, Miller said: “While I never intended to harm Congresswoman Ocasio-Cortez nor harm any members of the Capitol police force, I recognize that my social media posts were completely inappropriate.”

“I want to publicly apologize to Congresswoman Ocasio-Cortez and the Capitol police officers. I have always supported law enforcement and I am ashamed by my comments,” he added.

During an Instagram Live last week, Ocasio-Cortez said that a “close encounter” led her to fear she was “going to die” during the insurrection. It is not clear if the person she was referring to was Miller. As of Monday evening, she hadn’t commented on Miller’s apology.

Miller was arrested last Wednesday and charged with four counts including violent entry and disorderly conduct on Capitol grounds.

In his statement, he said he was not armed when he entered the Capitol and that he stayed in the rotunda. He claimed he went back to Texas after “President Trump asked us to go home.”

Miller said he had never been very interested in politics until recently, but that Trump’s election fraud accusations “really got to me and I felt I had to support him.”

However, he also said he is “solely responsible” for his actions and that “there are no excuses for what I did” before offering to testify at any trial or congressional proceeding.

Also on HuffPost

This article originally appeared on HuffPost and has been updated.

Latest Stories

  • TriMas Announces Departure of Josh Sherbin, Senior Vice President, General Counsel and Chief Compliance Officer

    TriMas (NASDAQ: TRS) today announced that Joshua Sherbin, Senior Vice President, General Counsel and Chief Compliance Officer, is leaving TriMas.

  • Team Collaboration Software Market is Expected to Reach $26.49 Billion by 2027, Says AMR

    Rise in adoption of cloud-based software as service (SaaS), major shift toward virtual businesses due to covid-19 pandemic, and increase in popularity of team collaboration software to reduce administration and maintenance drive the growth of the global team collaboration software market. Moreover, the market across North America region dominated in 2019 with highest market share, and is expected to lead the trail throughout the forecast period.Portland, OR, March 03, 2021 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global team collaboration software industry was pegged at $9.87 billion in 2019, and is expected to reach $26.49 billion by 2027, at a CAGR of 13.2% from 2020 to 2027. The report provides an in-depth analysis of changing market dynamics, key investment pockets, top segments, value chain, and competitive landscape. Rise in adoption of cloud-based software as service (SaaS), major shift toward virtual businesses due to covid-19 pandemic, and increase in popularity of team collaboration software to reduce administration and maintenance drive the growth of the global team collaboration software market. However, lack of IT infrastructure in developing regions restrains the growth. Moreover, integration of advanced technologies in team collaboration software is anticipated to present lucrative opportunities in the near future. Download Sample Report: https://www.alliedmarketresearch.com/request-sample/5977 Impact of Covid-19 on Team collaboration Software Market: The demand for team collaboration software has increased during the pandemic thereby augmenting the market growth.The prolonged lockdowns and restrictions have further fueled the adoption of team collaboration software market. Get detailed COVID-19 impact analysis on the Team Collaboration Software Market: https://www.alliedmarketresearch.com/request-for-customization/5977?reqfor=covid The team collaboration software market is segmented on the basis of component, deployment, software type, industry vertical, and region. Based on deployment mode, the cloud segment held the highest market share with nearly three-fifths of the global market revenue in 2019 and is anticipated to lead by the end of 2027. Additionally, the segment is also expected to showcase the fastest CAGR of 14.3% throughout the forecast period. Based on software type, the communication and co-ordination segment dominated the market with more than half of the global market share in 2019, and is expected to maintain its dominance by 2027.However, the conferencing segment is projected to portray the fastest CAGR of 14.8% throughout 2027. For Purchase Inquiry: https://www.alliedmarketresearch.com/purchase-enquiry/5977 Based on geography, the market is studied across Asia-Pacific, North America, Europe, and LAMEA. The North America region held the lion’s share in 2019, with nearly two-fifths of the global market. The region is anticipated to lead the trail throughout the forecast period. On the other hand, the market across Asia-Pacific is estimated to register the fastest CAGR of 17.9% during the forecast period. The major market players profiled in the report include IBM Corporation, Microsoft Corporation, MindMeld Inc., Oracle Corporation, Slack Technologies, Inc., SMART Technologies ULC, AT&T Intellectual Property, Cisco System Inc., Citrix Systems Inc., and Google LLC. AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model): AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports. Get an access to the library of reports at any time from any device and anywhere. For more details, follow the link: https://www.alliedmarketresearch.com/library-access About Allied Market Research: Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry. Contact: David Correa5933 NE Win Sivers Drive#205, Portland, OR 97220United StatesToll Free: +1-800-792-5285UK: +44-845-528-1300Hong Kong: +852-301-84916India (Pune): +91-20-66346060Fax: +1-855-550-5975help@alliedmarketresearch.com Web: https://www.alliedmarketresearch.com Follow Us on: LinkedIn Twitter

  • Global Polyurethane (CAS 53504-41-9) Market Report 2021: Trends and Developments, Major Players, Main Downstream Sectors, Pricing Analysis, Manufacturing Methods, Distributors - ResearchAndMarkets.com

    The "Polyurethane (CAS 53504-41-9) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.

  • Gold Rush Cariboo Corp. Announces Upsize to Non-Brokered Private Placement of Special Warrants

    Toronto, Ontario--(Newsfile Corp. - March 3, 2021) - Gold Rush Cariboo Corp. (TSXV: GDBO) (OTC: SGRWF) ("Gold Rush" or the "Company") is pleased to announce that further to its press release of February 9, 2021, the Company has increased the size of its private placement offering (the "Offering") to gross proceeds of up to $1,150,000 through the issuance of up to 76,666,666 special warrants (the "Special Warrants") at a price of $0.015 per Special ...

  • Camilla Gives Update on Prince Philip: He's 'Slightly Improving' but It 'Hurts at Moments'

    The Duke of Edinburgh, 99, has now spent 15 nights in the hospital

  • Tax burden set to be highest since the 1960s after Sunak’s Budget

    Rishi Sunak said that without ‘corrective action’ the national debt would rise indefinitely.

  • Nick Jonas Reveals That 'Missing' Wife Priyanka Chopra and Feeling 'Disocnnected' Inspired His New Album

    Nick Jonas explained that he "dug" into writing new music while his wife was away filming The Matrix 4

  • FIR lodged against Rakhi Sawant, brother for alleged fraud of Rs 7 lakh; reality TV star to file a defamation case

    The FIR filed by a retired bank employee Shailesh Srivastava alleges that Rakhi, Rakesh and a man named Raj Khatri taken Rs 6 lakhs from him and in return given him a post-dated-cheque for the renovation of a dance institute in Delhi's Vikaspuri.

  • Texas no longer has a mask mandate — but here are some major businesses requiring them

    Businesses are still allowed to enforce safety measures after the new mandate goes into effect March 10.

  • U.K. Retail-Credit Outlook Boosted Ahead of Government Spending Spree

    (Bloomberg) -- Credit investors are returning to the corporate issuers that dominate U.K. retail as a government budget announcement on Wednesday offered further financial relief for the Covid-battered sector.Chancellor of the Exchequer Rishi Sunak unveiled plans for 5 billion pounds ($7 billion) of grants for eligible businesses in sectors including retail and hospitality in today’s budget, as well as an extension of the business-rates holiday for those sectors. He also ruled out any immediate tax hikes or spending cuts.The announcement was largely welcomed by fund managers holding bonds of U.K. corporates. Companies in the country’s hospitality, leisure and retail industries were already beginning to show signs of improvement after taking a hammering in 2020, while the cost of insuring debt against default across most U.K. retail-linked bonds has also been falling since the start of the year.“Credit investors will take some comfort from today’s budget as short term measures are again supplemented to weather the immediate effects of the pandemic,” said Fraser Lundie, Head of Credit at the international business of Federated Hermes.Still, with the longer term outlook for the U.K. economy so uncertain, Lundie added that it was a question of assessing each credit on its merits. “Sectors most levered to the recovery, including hospitality and construction, remain a ‘show me story’,” he said.Tatjana Greil Castro, co-head of public markets and a portfolio manager at Muzinich & Co. Ltd., which has $39 billion in assets under management, said that she sees a buying opportunity in U.K assets again particularly in travel, leisure and real estate-related sectors, and has started adding U.K risk back into her portfolios.“The country seems to be ahead with regards to its vaccine rollout and U.K names are still trading wide so offer some potential value,” Greil Castro said. “We’ve been focusing on the re-opening trade in the U.K and the budget confirms our optimism as the government doesn’t pull support prematurely.”Retail RewardedRetail and leisure industry credits have advanced since the start of the year. Bonds of pub company Stonegate, retailer Matalan Plc and fitness operator Pure Gym Group Plc were among the best-performing in the high-yield sterling market in February. Stonegate’s bonds rose by 3 pence on the pound and are bid above their face value at 104 pence, according to data compiled by Bloomberg.The cost of insuring Stonegate and Marks & Spencer Group Plc debt against default has dropped significantly since the start of the year. Stonegate’s swaps fell by 47 basis points since early February, with the contracts now quoted at about 556 basis points.“I think there’s a bit of a Goldilocks scenario priced in,” said Neill Keaney, a credit analyst at CreditSights in London. “Investors are looking to a reopening bounce but also continued support until the end of first half of 2020 at least.”(Updates throughout with reaction to budget, adds chart)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • Global GMP Cell Banking Services Industry

    Global GMP Cell Banking Services Market to Reach US$992. 7 Million by the Year 2027. Amid the COVID-19 crisis, the global market for GMP Cell Banking Services estimated at US$402. 7 Million in the year 2020, is projected to reach a revised size of US$992.New York, March 03, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global GMP Cell Banking Services Industry" - https://www.reportlinker.com/p05956870/?utm_source=GNW 7 Million by 2027, growing at a CAGR of 13.8% over the analysis period 2020-2027.Mammalian, one of the segments analyzed in the report, is projected to grow at a 14.7% CAGR to reach US$665.4 Million by the end of the analysis period.After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Microbial segment is readjusted to a revised 12.7% CAGR for the next 7-year period. This segment currently accounts for a 13.2% share of the global GMP Cell Banking Services market. The U.S. Accounts for Over 29.6% of Global Market Size in 2020, While China is Forecast to Grow at a 13.2% CAGR for the Period of 2020-2027 The GMP Cell Banking Services market in the U.S. is estimated at US$119 Million in the year 2020. The country currently accounts for a 29.56% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$172.3 Million in the year 2027 trailing a CAGR of 13.2% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 12.1% and 11.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 10% CAGR while Rest of European market (as defined in the study) will reach US$172.3 Million by the year 2027. Insect Segment Corners a 5.7% Share in 2020 In the global Insect segment, USA, Canada, Japan, China and Europe will drive the 14% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$18.5 Million in the year 2020 will reach a projected size of US$46.4 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$117.7 Million by the year 2027.We bring years of research experience to this 7th edition of our report. The 182-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed. Competitors identified in this market include, among others, Austrianova Singapore Pte Ltd.Charles River Laboratories International, Inc.Eurofins Scientific SEGoodwin Biotechnology, Inc.Lonza Group AGMerck KgaAParagon Bioservices, Inc.SGS India Pvt. Ltd.ViruSure GmbHWuXi AppTec Read the full report: https://www.reportlinker.com/p05956870/?utm_source=GNW I. INTRODUCTION, METHODOLOGY & REPORT SCOPE II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Impact of Covid-19 and a Looming Global Recession Global Competitor Market Shares GMP Cell Banking Services Competitor Market Share Scenario Worldwide (in %): 2018E 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for GMP Cell Banking Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 Table 2: World Historic Review for GMP Cell Banking Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 3: World 15-Year Perspective for GMP Cell Banking Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2018 & 2027 Table 4: World Current & Future Analysis for Mammalian by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 Table 5: World Historic Review for Mammalian by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 6: World 15-Year Perspective for Mammalian by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027 Table 7: World Current & Future Analysis for Microbial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 Table 8: World Historic Review for Microbial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 9: World 15-Year Perspective for Microbial by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027 Table 10: World Current & Future Analysis for Insect by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 Table 11: World Historic Review for Insect by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 12: World 15-Year Perspective for Insect by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027 Table 13: World Current & Future Analysis for Yeast by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 Table 14: World Historic Review for Yeast by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 15: World 15-Year Perspective for Yeast by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027 Table 16: World Current & Future Analysis for Avian by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 Table 17: World Historic Review for Avian by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 18: World 15-Year Perspective for Avian by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027 Table 19: World Current & Future Analysis for Other Cell Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 Table 20: World Historic Review for Other Cell Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 21: World 15-Year Perspective for Other Cell Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027 Table 22: World Current & Future Analysis for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 Table 23: World Historic Review for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 24: World 15-Year Perspective for Biopharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027 Table 25: World Current & Future Analysis for Contract Manufacturing Organizations (CMOs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 Table 26: World Historic Review for Contract Manufacturing Organizations (CMOs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 27: World 15-Year Perspective for Contract Manufacturing Organizations (CMOs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027 III. MARKET ANALYSIS GEOGRAPHIC MARKET ANALYSIS UNITED STATES Market Facts & Figures US GMP Cell Banking Services Market Share (in %) by Company: 2018 & 2027 Market Analytics Table 28: USA Current & Future Analysis for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Insect, Yeast, Avian and Other Cell Types - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 29: USA Historic Review for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Insect, Yeast, Avian and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 30: USA 15-Year Perspective for GMP Cell Banking Services by Cell Type - Percentage Breakdown of Value Sales for Mammalian, Microbial, Insect, Yeast, Avian and Other Cell Types for the Years 2012, 2018 & 2027 Table 31: USA Current & Future Analysis for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations (CMOs) - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 32: USA Historic Review for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations (CMOs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 33: USA 15-Year Perspective for GMP Cell Banking Services by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies and Contract Manufacturing Organizations (CMOs) for the Years 2012, 2018 & 2027 CANADA Table 34: Canada Current & Future Analysis for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Insect, Yeast, Avian and Other Cell Types - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 35: Canada Historic Review for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Insect, Yeast, Avian and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 36: Canada 15-Year Perspective for GMP Cell Banking Services by Cell Type - Percentage Breakdown of Value Sales for Mammalian, Microbial, Insect, Yeast, Avian and Other Cell Types for the Years 2012, 2018 & 2027 Table 37: Canada Current & Future Analysis for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations (CMOs) - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 38: Canada Historic Review for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations (CMOs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 39: Canada 15-Year Perspective for GMP Cell Banking Services by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies and Contract Manufacturing Organizations (CMOs) for the Years 2012, 2018 & 2027 JAPAN Table 40: Japan Current & Future Analysis for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Insect, Yeast, Avian and Other Cell Types - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 41: Japan Historic Review for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Insect, Yeast, Avian and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 42: Japan 15-Year Perspective for GMP Cell Banking Services by Cell Type - Percentage Breakdown of Value Sales for Mammalian, Microbial, Insect, Yeast, Avian and Other Cell Types for the Years 2012, 2018 & 2027 Table 43: Japan Current & Future Analysis for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations (CMOs) - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 44: Japan Historic Review for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations (CMOs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 45: Japan 15-Year Perspective for GMP Cell Banking Services by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies and Contract Manufacturing Organizations (CMOs) for the Years 2012, 2018 & 2027 CHINA Table 46: China Current & Future Analysis for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Insect, Yeast, Avian and Other Cell Types - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 47: China Historic Review for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Insect, Yeast, Avian and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 48: China 15-Year Perspective for GMP Cell Banking Services by Cell Type - Percentage Breakdown of Value Sales for Mammalian, Microbial, Insect, Yeast, Avian and Other Cell Types for the Years 2012, 2018 & 2027 Table 49: China Current & Future Analysis for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations (CMOs) - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 50: China Historic Review for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations (CMOs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 51: China 15-Year Perspective for GMP Cell Banking Services by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies and Contract Manufacturing Organizations (CMOs) for the Years 2012, 2018 & 2027 EUROPE Market Facts & Figures European GMP Cell Banking Services Market: Competitor Market Share Scenario (in %) for 2018 & 2027 Market Analytics Table 52: Europe Current & Future Analysis for GMP Cell Banking Services by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 Table 53: Europe Historic Review for GMP Cell Banking Services by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 54: Europe 15-Year Perspective for GMP Cell Banking Services by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2018 & 2027 Table 55: Europe Current & Future Analysis for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Insect, Yeast, Avian and Other Cell Types - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 56: Europe Historic Review for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Insect, Yeast, Avian and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 57: Europe 15-Year Perspective for GMP Cell Banking Services by Cell Type - Percentage Breakdown of Value Sales for Mammalian, Microbial, Insect, Yeast, Avian and Other Cell Types for the Years 2012, 2018 & 2027 Table 58: Europe Current & Future Analysis for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations (CMOs) - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 59: Europe Historic Review for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations (CMOs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 60: Europe 15-Year Perspective for GMP Cell Banking Services by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies and Contract Manufacturing Organizations (CMOs) for the Years 2012, 2018 & 2027 FRANCE Table 61: France Current & Future Analysis for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Insect, Yeast, Avian and Other Cell Types - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 62: France Historic Review for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Insect, Yeast, Avian and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 63: France 15-Year Perspective for GMP Cell Banking Services by Cell Type - Percentage Breakdown of Value Sales for Mammalian, Microbial, Insect, Yeast, Avian and Other Cell Types for the Years 2012, 2018 & 2027 Table 64: France Current & Future Analysis for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations (CMOs) - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 65: France Historic Review for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations (CMOs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 66: France 15-Year Perspective for GMP Cell Banking Services by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies and Contract Manufacturing Organizations (CMOs) for the Years 2012, 2018 & 2027 GERMANY Table 67: Germany Current & Future Analysis for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Insect, Yeast, Avian and Other Cell Types - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 68: Germany Historic Review for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Insect, Yeast, Avian and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 69: Germany 15-Year Perspective for GMP Cell Banking Services by Cell Type - Percentage Breakdown of Value Sales for Mammalian, Microbial, Insect, Yeast, Avian and Other Cell Types for the Years 2012, 2018 & 2027 Table 70: Germany Current & Future Analysis for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations (CMOs) - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 71: Germany Historic Review for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations (CMOs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 72: Germany 15-Year Perspective for GMP Cell Banking Services by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies and Contract Manufacturing Organizations (CMOs) for the Years 2012, 2018 & 2027 ITALY Table 73: Italy Current & Future Analysis for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Insect, Yeast, Avian and Other Cell Types - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 74: Italy Historic Review for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Insect, Yeast, Avian and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 75: Italy 15-Year Perspective for GMP Cell Banking Services by Cell Type - Percentage Breakdown of Value Sales for Mammalian, Microbial, Insect, Yeast, Avian and Other Cell Types for the Years 2012, 2018 & 2027 Table 76: Italy Current & Future Analysis for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations (CMOs) - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 77: Italy Historic Review for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations (CMOs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 78: Italy 15-Year Perspective for GMP Cell Banking Services by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies and Contract Manufacturing Organizations (CMOs) for the Years 2012, 2018 & 2027 UNITED KINGDOM Table 79: UK Current & Future Analysis for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Insect, Yeast, Avian and Other Cell Types - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 80: UK Historic Review for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Insect, Yeast, Avian and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 81: UK 15-Year Perspective for GMP Cell Banking Services by Cell Type - Percentage Breakdown of Value Sales for Mammalian, Microbial, Insect, Yeast, Avian and Other Cell Types for the Years 2012, 2018 & 2027 Table 82: UK Current & Future Analysis for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations (CMOs) - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 83: UK Historic Review for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations (CMOs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 84: UK 15-Year Perspective for GMP Cell Banking Services by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies and Contract Manufacturing Organizations (CMOs) for the Years 2012, 2018 & 2027 REST OF EUROPE Table 85: Rest of Europe Current & Future Analysis for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Insect, Yeast, Avian and Other Cell Types - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 86: Rest of Europe Historic Review for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Insect, Yeast, Avian and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 87: Rest of Europe 15-Year Perspective for GMP Cell Banking Services by Cell Type - Percentage Breakdown of Value Sales for Mammalian, Microbial, Insect, Yeast, Avian and Other Cell Types for the Years 2012, 2018 & 2027 Table 88: Rest of Europe Current & Future Analysis for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations (CMOs) - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 89: Rest of Europe Historic Review for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations (CMOs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 90: Rest of Europe 15-Year Perspective for GMP Cell Banking Services by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies and Contract Manufacturing Organizations (CMOs) for the Years 2012, 2018 & 2027 ASIA-PACIFIC Table 91: Asia-Pacific Current & Future Analysis for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Insect, Yeast, Avian and Other Cell Types - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 92: Asia-Pacific Historic Review for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Insect, Yeast, Avian and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 93: Asia-Pacific 15-Year Perspective for GMP Cell Banking Services by Cell Type - Percentage Breakdown of Value Sales for Mammalian, Microbial, Insect, Yeast, Avian and Other Cell Types for the Years 2012, 2018 & 2027 Table 94: Asia-Pacific Current & Future Analysis for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations (CMOs) - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 95: Asia-Pacific Historic Review for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations (CMOs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 96: Asia-Pacific 15-Year Perspective for GMP Cell Banking Services by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies and Contract Manufacturing Organizations (CMOs) for the Years 2012, 2018 & 2027 REST OF WORLD Table 97: Rest of World Current & Future Analysis for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Insect, Yeast, Avian and Other Cell Types - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 98: Rest of World Historic Review for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Insect, Yeast, Avian and Other Cell Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 99: Rest of World 15-Year Perspective for GMP Cell Banking Services by Cell Type - Percentage Breakdown of Value Sales for Mammalian, Microbial, Insect, Yeast, Avian and Other Cell Types for the Years 2012, 2018 & 2027 Table 100: Rest of World Current & Future Analysis for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations (CMOs) - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 101: Rest of World Historic Review for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations (CMOs) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 102: Rest of World 15-Year Perspective for GMP Cell Banking Services by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies and Contract Manufacturing Organizations (CMOs) for the Years 2012, 2018 & 2027 IV. COMPETITION Total Companies Profiled: 65Read the full report: https://www.reportlinker.com/p05956870/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

  • When does the stamp duty holiday in England and Northern Ireland end?

    The chancellor has announced an extension to the stamp duty holiday?

  • Stamp duty holiday extended to end of June

    After June there will be tapered relief for the next three months, the chancellor announces.

  • Budget 2021: Business rates holiday extended to June

    The chancellor's business rates holiday for England will run for another three months.

  • Minerco Retains Investor Relations Partners as Investor Relations Counsel

    Ann Arbor, Michigan--(Newsfile Corp. - March 3, 2021) - Minerco (OTC Pink: MINE) today announced that it has retained Investor Relations Partners (IRP) to provide investor relations and capital markets advisory services to the Company. "We believe the current year will be one of the most historical for the psilocybin mushroom industry and, as a result, the most pivotal for Minerco and its shareholders," said Julius Jenge, Chief Executive Officer of Minerco, Inc. ...

  • Stocks Decline as Bond Yields Spike; Dollar Gains: Markets Wrap

    (Bloomberg) -- Stocks fell as a surge in Treasury yields added to concern over stretched valuations amid an uneven economic rebound from a pandemic-induced recession. The dollar climbed.The S&P 500 extended losses into a second day as benchmark 10-year yields jumped to as high as 1.4790%. Earlier Wednesday, equity futures dropped on data showing the number of employees at U.S. businesses rose in February by less than expected. The Nasdaq 100 underperformed, while Boeing Co. and Goldman Sachs Group Inc. led gains in the Dow Jones Industrial Average. Cryptocurrency-exposed shares surged, with Bitcoin topping $50,000.Wednesday’s jobs reading indicate that employment gains continue to be held back by pandemic-related constraints on businesses and economic activity. Even so, many analysts expect a meaningful improvement in the labor market in the coming months as Covid-19 vaccinations pick up and virus concerns ease. The Senate is planning to formally open debate on President Joe Biden’s pandemic-relief bill as soon as Wednesday afternoon.“The markets have been all over the place for the past few days, alternating between ‘risk-on’ and ‘risk-off’ as investors have tried to weigh the impact of rising yields against the prospects of a strong economic rebound with the ongoing Covid vaccine rollouts,” said Fawad Razaqzada, an analyst at ThinkMarkets.Read: Actually, the Options Market Isn’t That Complacent: Taking StockBuying U.S. stocks with borrowed money has yet to become excessive even after a bull-market surge, according to Stephen Suttmeier, a Bank of America Corp. analyst. He cited a comparison between the total amount of margin debt and the S&P 500’s market value in a report Monday. Margin loans increased 66% to a record $798.6 billion for the 10 months ended in January, data compiled by the Financial Industry Regulatory Authority show. The latest total equaled 2.5% of the S&P 500’s value, below a peak of 3.1% in January 2014.“Investors are not over-levered,” Suttmeier wrote.Some key events to watch this week:OPEC+ meeting on output Thursday.U.S. factory orders, initial jobless claims and durable goods orders are due Thursday.The February U.S. employment report on Friday will provide an update on the speed and direction of the nation’s labor market recovery.These are some of the main moves in markets:StocksThe S&P 500 Index fell 0.3% as of 9:44 a.m. New York time.The Stoxx Europe 600 Index decreased 0.2%.The MSCI Asia Pacific Index gained 1.2%.The MSCI Emerging Market Index advanced 1.5%.CurrenciesThe Bloomberg Dollar Spot Index increased 0.3%.The euro declined 0.4% to $1.2048.The Japanese yen depreciated 0.2% to 106.93 per dollar.BondsThe yield on 10-year Treasuries rose eight basis points to 1.47%.Germany’s 10-year yield climbed four basis points to -0.32%.Britain’s 10-year yield advanced seven basis points to 0.761%.CommoditiesWest Texas Intermediate crude advanced 1% to $60.34 a barrel.Gold slid 1.4% to $1,713.59 an ounce.Silver fell 2.2% to $26.17 per ounce.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • Middle managers are the ones who make or break immigrant-inclusive teams, report finds

    Toronto, ON, March 03, 2021 (GLOBE NEWSWIRE) -- The one group that makes (or breaks) efforts to build immigrant-inclusive teams in the workplace is middle managers, according to a new report published by the Toronto Region Immigrant Employment Council (TRIEC). While workplace inclusion starts at the top with executive leadership, it is the everyday choices and actions of middle managers that pave the way to success or failure when it comes to immigrant professionals reaching their full potential. This group has significant influence over what happens after an immigrant is hired, whether they feel part of their team, offering the feedback they need to grow, and ultimately the extent to which they progress in the organization. The report, Make or Break: How middle managers and executives can build immigrant-inclusive teams, is the first of its kind to look at the role of middle management through the lens of immigrant inclusion. Through original research – including 30 key informant interviews – as well as an extensive literature review, the report shares practical actions that management can take to positively form and lead immigrant-inclusive teams – and how executives can support them. “Middle managers are an interesting group to look at - while organizational change needs leadership from the top, they are not without power,” said Adwoa K. Buahene, CEO of TRIEC. “The beauty of this report is that it draws on the lived experience of people who understand all sides of this story – middle managers who are also immigrants, as well as experts in diversity and inclusion.” The report also reveals: Few organizations measure immigrant inclusion: Not enough workplaces measure how they’re faring in terms of hiring, retaining, and/or promoting immigrant professionals. Organizations lack data on immigrants as a distinct equity group.One-off D & I trainings are not enough: Immigrant inclusion efforts by middle managers have a greater chance of success if tied to organizational strategic goals and KPIs. Executives must seek to incentivize inclusive behaviour for middle managers, whether through financial perks, prospects of promotion, or recognition.Conscious and unconscious bias is a factor: Conscious and unconscious bias creates systemic barriers that prevent immigrants from entering and/or achieving their full potential in the workplace. While some employers have come a long way, preconceived ideas about international education, perceived lack of soft skills, and different accents still affect immigrants’ ability to progress. The report will be released to the public this afternoon at TRIEC’s Immigrant Inclusion Summit which is hosted virtually this year. Attended by GTA employers, employment service agencies, and leaders of professional immigrant associations, the agenda includes a keynote presentation by the report’s author, and a panel discussion. -30- About TRIEC Toronto Region Immigrant Employment Council (TRIEC) champions the talent and experience that immigrants bring to the Greater Toronto Area. We support organizations to become more inclusive, and help newcomers expand their professional networks and understand the local labour market. We collaborate with leaders and organizations to build a GTA where immigrant professionals can contribute to their fullest potential. CONTACT: Daniel Kim, Media Relations Lead Toronto Region Immigrant Employment Council (TRIEC) 416-931-5803 dkim@triec.ca

  • Global Kaposi Sarcoma Market (2021 to 2025) - Featuring Baxter International, Galen and GlaxoSmithKline Among Others - ResearchAndMarkets.com

    The "Global Kaposi Sarcoma Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.

  • Dragan Stojkovic appointed Serbia national football team coach in build-up to 2022 World Cup qualifying

    The 55-year-old Stojkovic replaces Ljubisa Tumbakovic, who was fired in December after the team failed to qualify for the European Championship in the playoffs.

  • Stocks are off to a mixed start on Wall Street, yields rise

    Stocks are off to a mixed start on Wall Street as gains for banks are offset by losses in technology companies and other parts of the market. The S&P 500 was down 0.2% after the first few minutes of trading Wednesday. The tech-heavy Nasdaq was down 0.5% and the Dow Jones Industrial Average was up 0.1%. Banks were benefiting from another tick higher in long-term interest rates in the bond market, which allows them to charge higher rates on mortgages and many other kinds of loans. The yield on the benchmark 10-year Treasury note rose to 1.48% from 1.41%. THIS IS A BREAKING NEWS UPDATE. AP’s earlier story follows below. BANGKOK (AP) — World stock markets and U.S. futures rose Wednesday after a Federal Reserve governor said the central bank is still far from raising interest rates. Expectations for stronger economic growth in coming months have fueled worries that interest rates will head higher. The yield on the 10-year Treasury was at 1.44% early Wednesday, having traded above 1.50% last week. “It feels like we are in the eye of the storm," analyst Stephen Innes of Axi said in a commentary. Investors have recently focused on selling high-priced technology shares but are also watching for policy changes as President Joe Biden's $1.9 billion stimulus package heads into the Senate after narrowly passing in the House. “How much overheating and inflation will the Biden fiscal stimulus generate remains at the top of virtually every market conversation," Innes said. Germany's DAX rose 0.9% to 14,165 and the CAC 40 in Paris added 0.8% to 5,850. Britain's FTSE 100 picked up 1% to 6,679 as the Treasury chief was expected to announce an extension to the furlough program that has helped millions avoid unemployment during the pandemic. The future for the S&P 500 climbed 0.6% and that for the Dow industrials was 0.7% higher. Higher interest rates make each $1 of profit that companies earn a little less valuable. That’s making Wall Street reconsider the value of technology stocks, in large part because their recent dominance left them looking even pricier than the rest of the market. Treasury yields have risen above 1.50% recently with expectations for economic growth and inflation, up from about 0.9% at the beginning of the year. Such a rise makes borrowing more expensive for homebuyers, companies taking out loans and virtually everyone else. That can slow economic growth. On Tuesday, Federal Reserve Governor Lael Brainard sought to calm financial markets by emphasizing that the Fed, while generally optimistic about the economy, is still far from raising interest rates or reducing its $120 billion a month in asset purchases. “We’ve got some distance to go to meet our goals,” of higher inflation and lower unemployment, Brainard said. Federal Reserve Chair Jerome Powell is scheduled to speak on Thursday, and at the end of the week will be the government’s jobs report, which is typically the highlight economic report of every month. It also includes numbers for how much wages are rising across the economy, a key component of inflation. In Asian trading, Hong Kong's Hang Seng rose 2.7% to 29,792.81. In Tokyo, the Nikkei 225 added 0.5% to 29,559.10, while the Kospi in Seoul picked up 1.3% to 3,082.99. The Shanghai Composite index advanced 2% to 3,576.90. Australia's S&P/ASX 200 gained 0.8% to 6,818.00 after the government reported the economy grew at a 3.1% quarterly rate, but a minus 1.1% annual rate, in the fourth quarter of last year. The better than expected result was helped by consumer demand and public spending, analysts said. India's Sensex rose 1.5% to 51,036.24. In other trading, U.S. benchmark crude oil rose $1.14 to $60.89 per barrel in electronic trading on the New York Mercantile Exchange. It lost 89 cents on Tuesday. Brent crude, the international standard, added $1.16 to $63.86 per barrel. The dollar rose to 106.99 Japanese yen from 106.68 yen late Tuesday. The euro fell to $1.2064 from $1.2091. The Associated Press